WHO Additional clarification on Covaxin needed decision likely on November 3
WHO : Additional clarification on Covaxin needed, decision likely on November 3 A World Health Organization technical advisory group was reviewing data on India’s Covaxin shot against COVID-19 with a decision on its emergency use listing likely soon, a spokesperson said. Millions of Indians have taken the shot produced by Bharat Biotech but many have been unable to travel pending the WHO approval.
“The WHO independent TAG met today & asked for additional clarifications from the manufacturer Bharat Biotech to conduct a final EUL risk-benefit assessment for global use of Covaxin. It will reconvene for the final assessment on Wednesday, 3 November if data is received soon,†WHO Chief Scientist Soumya Swaminathan tweeted.
The WHO has so far listed the Pfizer/BioNTech vaccine, two AstraZeneca/Oxford vaccines, AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India, COVID-19 vaccine Ad26.COV2.S developed by Janssen (Johnson & Johnson) and China’s Sinopharm for emergency use.
Previous articleU.S. â€" FDA backs Pfizer’s vaccine for children aged 5 â€" 11
Know What's Trending Today (Kwt Today) Web Desk reports news and views on trending topics from the Middle East and around the World.
0 Response to "WHO Additional clarification on Covaxin needed decision likely on November 3"
Post a Comment